Feature | May 14, 2014

Leadless Pacemaker Showing Promising Results After One Year

Follow-up results for Nanostim presented in late-breaking clinical trial presentation at Heart Rhythm 2014

May 14, 2014 — Vivek Reddy, M.D., director of arrhythmia services for The Mount Sinai Hospital, reported promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Reddy presented the one-year LEADLESS study data findings during a late-breaking clinical trial presentation on Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim leadless pacemaker at hospitals in Prague and in Amsterdam. The findings, which assessed device performance and patient outcomes through 12 months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace or communicate with the pacemaker.

"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology, and our results show the leadless pacemaker is comparable to traditional pacemakers," says Reddy, who is the study's co-investigator and chairman of its steering committee. "Our latest findings further support the promising performance and safety of this minimally invasive, nonsurgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials."

In February, Reddy was the first to implant the leadless pacemaker in the United States. The multicenter clinical trial LEADLESS II aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the United States and Canada.

The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than 10 percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms, and if the heartbeat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.

In comparison to a conventional pacemaker, the leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.

The LEADLESS study was funded by St. Jude Medical, manufacturer of the Nanostim pacemaker. Reddy receives financial compensation as a consultant and advisory board member for St. Jude Medical. In addition, in 2013 he received one-time financial compensation from St. Jude Medical in the form of an option buyout relating to St. Jude Medical's acquisition of Nanostim.

For more information: www.mountsinai.org, www.sjm.com

Related Content

anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
Boston Scientific, FDA, IntelliNav XP ablation catheters, Rhythmia Mapping System

Rhythmia Mapping System image courtesy of Boston Scientific

Technology | Ablation Systems| May 23, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
News | Atrial Fibrillation| May 19, 2016
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision...
Johns Hopkins, virtual heart modeling tool, VARP, arrhythmias, implanted defibrillator

Examples of how the computer model would classify one patient at high risk for heart arrhythmia and another at low risk. Image courtesy of Royc Faddis/Johns Hopkins University.

News | Cardiac Diagnostics| May 17, 2016
May 17, 2016 — An interdisciplinary Johns Hopkins University team has developed a...
News | Ablation Systems| May 11, 2016
Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are...
Medtronic, FDA approval, MR-conditional CRT-Ds, defibrillators, Amplia, Compia
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2016
Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only...
Imricor, Vision-MR ablation catheter, clinical study, MRI guidance
News | Ablation Systems| May 10, 2016
Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR...
Medtronic, Micra transcatheter pacing system, study data, HRS 2016
News | Pacemakers| May 10, 2016
Medtronic plc announced clinical results highlighting the strong safety and performance profile of the miniaturized...
LivaNova, SonR hemodynamic sensor, CRT, heart failure, RESPOND CRT trial, HRS 2016
News | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2016
The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in...
Overlay Init